US 11,690,810 B2
Combination treatment of bacterial infection
Margaret Ip, Hong Kong (CN); Kwok Pui Fung, Hong Kong (CN); Ping Chung Leung, Hong Kong (CN); Clara Bik San Lau, Hong Kong (CN); Quan Bin Han, Hong Kong (CN); Chung Lap Chan, Hong Kong (CN); Chit Tsui, Hong Kong (CN); and Quande Wang, Xiangtan (CN)
Assigned to The Chinese University of Hong Kong, Hong Kong (CN)
Filed by The Chinese University of Hong Kong, Hong Kong (CN)
Filed on Nov. 14, 2019, as Appl. No. 16/684,073.
Claims priority of provisional application 62/767,122, filed on Nov. 14, 2018.
Prior Publication US 2020/0155641 A1, May 21, 2020
Int. Cl. A61K 31/12 (2006.01); A61K 38/14 (2006.01); A61P 31/04 (2006.01); A61K 31/353 (2006.01); A61K 31/575 (2006.01); A61K 31/7036 (2006.01); A61K 31/192 (2006.01); A61K 31/352 (2006.01); A61K 31/43 (2006.01); A61K 31/58 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/12 (2013.01) [A61K 31/192 (2013.01); A61K 31/352 (2013.01); A61K 31/353 (2013.01); A61K 31/43 (2013.01); A61K 31/575 (2013.01); A61K 31/58 (2013.01); A61K 31/7036 (2013.01); A61K 38/14 (2013.01); A61P 31/04 (2018.01); A61K 45/06 (2013.01)] 20 Claims
 
1. A method for suppressing growth of methicillin-resistant Staphylococcus aureus (MRSA), comprising contacting the MRSA with kuraridin in a concentration of about 1-4 μg/ml and epicatechin gallate (ECG) in a concentration of about 0.25-8 μg/ml, optionally further with an antibiotic in an effective amount.